Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$3.90 -0.8%	$3.70	$2.12 ▼ $5.80	$387.38M	1.99	998,870 shs	791,786 shs
CYDY CytoDyn	$0.26 -1.7%	$0.31	$0.10 ▼ $0.49	$322.89M	1.23	1.17 million shs	1.32 million shs
ESPR Esperion Therapeutics	$1.87 +3.3%	$1.24	$0.69 ▼ $3.94	$370.63M	0.82	5.63 million shs	5.15 million shs
IPHYF Innate Pharma	$1.31	$1.52	$1.31 ▼ $1.95	$109.82M	0.47	N/A	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	0.00%	+2.09%	-3.23%	+39.78%	+13.70%
CYDY CytoDyn	0.00%	-12.00%	-19.08%	-35.46%	+96.41%
ESPR Esperion Therapeutics	0.00%	+33.57%	+50.81%	+134.28%	-4.59%
IPHYF Innate Pharma	0.00%	0.00%	0.00%	-9.66%	-32.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.8169 of 5 stars	3.5	3.0	0.0	0.0	2.4	0.0	0.0
CYDY CytoDyn	0.1706 of 5 stars	0.0	1.0	0.0	0.0	1.1	0.0	1.3
ESPR Esperion Therapeutics	4.1569 of 5 stars	3.4	3.0	0.0	3.9	3.2	1.7	0.6
IPHYF Innate Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	160.07% Upside
CYDY CytoDyn	0.00	N/A	N/A	N/A
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	274.33% Upside
IPHYF Innate Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPHYF, AQST, ESPR, and CYDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	6.73	N/A	N/A	($0.66) per share	-5.91
CYDY CytoDyn	N/A	N/A	$0.00 per share	77.28	($0.08) per share	N/A
ESPR Esperion Therapeutics	$332.31M	1.12	$0.02 per share	77.83	($1.97) per share	-0.95
IPHYF Innate Pharma	$21.77M	5.04	N/A	N/A	$0.11 per share	11.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	N/A	-100.02%	N/A	-50.31%	8/11/2025 (Estimated)
CYDY CytoDyn	$3.74M	$0.01	25.78	∞	N/A	N/A	N/A	-4.40%	8/13/2025 (Estimated)
ESPR Esperion Therapeutics	-$51.74M	-$0.49	N/A	N/A	N/A	-35.84%	-0.91%	-28.84%	N/A
IPHYF Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)

Latest IPHYF, AQST, ESPR, and CYDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	N/A	N/A	N/A	$11.32 million	N/A
8/5/2025	Q2 2025	ESPR Esperion Therapeutics	-$0.17	-$0.02	+$0.15	-$0.02	$62.55 million	$82.39 million
7/25/2025	Q4 2025	CYDY CytoDyn	N/A	-$0.01	N/A	-$0.01	N/A	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHYF Innate Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	4.87	4.48
CYDY CytoDyn	N/A	0.25	0.25
ESPR Esperion Therapeutics	N/A	1.18	0.81
IPHYF Innate Pharma	N/A	2.60	2.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
CYDY CytoDyn	5.06%
ESPR Esperion Therapeutics	47.39%
IPHYF Innate Pharma	N/A

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	8.35%
CYDY CytoDyn	0.54%
ESPR Esperion Therapeutics	1.70%
IPHYF Innate Pharma	31.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.03 million	Optionable
CYDY CytoDyn	20	1.25 billion	1.25 billion	Not Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
IPHYF Innate Pharma	179	83.83 million	57.10 million	Not Optionable

IPHYF, AQST, ESPR, and CYDY Headlines

Recent News About These Companies

Innate Pharma Joins BTIG Virtual Biotechnology Conference

July 29, 2025 | tipranks.com

Innate Pharma S.A. (IPHYF) - Yahoo Finance

July 11, 2025 | au.finance.yahoo.com

Innate Pharma SA: Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences

May 27, 2025 | finanznachrichten.de

Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F

April 30, 2025 | uk.finance.yahoo.com

Innate Pharma announces EUR 15M capital increase from Sanofi

April 24, 2025 | markets.businessinsider.com

Changes to Innate Pharma and Sanofi ANKET collaboration

April 23, 2025 | thepharmaletter.comT

Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company

April 23, 2025 | uk.finance.yahoo.com

Innate Pharma SA: Innate Pharma Reports Full Year 2024 Financial Results and Business Update

March 27, 2025 | finanznachrichten.de

Innate Pharma Shares Rise After Breakthrough Therapy Designation for Lacutamab

February 19, 2025 | marketwatch.com

US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome

February 18, 2025 | pharmabiz.comP

3 Promising Penny Stocks With Market Caps Under US$500M

January 31, 2025 | finance.yahoo.com

Innate Pharma doses first patient in Nectin-4 ADC trial

January 27, 2025 | clinicaltrialsarena.comC

Innate Pharma shares retain Buy rating on long-term strategy

January 17, 2025 | msn.com

The IPHA Stock Mystery: Why Did IPHA Surge Today?

December 16, 2024 | bovnews.comB

Innate Pharma & IFLI enter agreement to clinically study the potential of IPH6501, Innate's anti-CD20 ANKET in follicular lymphoma

December 9, 2024 | pharmabiz.comP

Positive Outlook for Innate Pharma: Buy Rating Supported by Promising Lacutamab Phase 2 Results and Strong Financial Position

December 9, 2024 | markets.businessinsider.com

Innate Pharma SA’s Innovations Spotlighted at ASH 2024

December 3, 2024 | msn.com

Innate Pharma’s Groundbreaking NK Cell Therapy for B-NHL

November 20, 2024 | zenopa.comZ

Evercore ISI Sticks to Its Buy Rating for Innate Pharma (IPHA)

November 14, 2024 | markets.businessinsider.com

Innate Pharma’s New CEO and Promising FDA Feedback

November 14, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHYF, AQST, ESPR, and CYDY Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$3.90 -0.03 (-0.76%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$3.90 0.00 (-0.13%)

As of 08/8/2025 07:47 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

CytoDyn OTCMKTS:CYDY

$0.26 0.00 (-1.72%)

As of 08/8/2025 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Esperion Therapeutics NASDAQ:ESPR

$1.87 +0.06 (+3.31%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.86 -0.02 (-0.80%)

As of 08/8/2025 07:59 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Innate Pharma OTCMKTS:IPHYF

$1.31 0.00 (0.00%)

As of 08/8/2025

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time